לברסט

País: Israel

Idioma: hebreo

Fuente: Ministry of Health

Ingredientes activos:

LETROZOLE 2.5 MG

Disponible desde:

RAFA LABORATORIES LTD

Código ATC:

L02BG04

formulario farmacéutico:

FILM COATED TABLETS

Vía de administración:

PER OS

Fabricado por:

SIEGFRIED GENERICS ( MALTA) LTD

Grupo terapéutico:

LETROZOLE

indicaciones terapéuticas:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Fecha de autorización:

2012-04-01